PREVENTROP
New approach to treatment of the blinding disease Retinopathy of Prematurity (ROP)
| Coordinatore | GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Totale costo | 7˙590˙759 € |
| EC contributo | 5˙990˙236 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | coordinator | 874˙314.41 |
| 2 |
SMERUD MEDICAL RESEARCH INTERNATIONAL AS
Organization address
address: DRAMMENSVEIEN 41 contact info |
NO (OSLO) | participant | 805˙200.00 |
| 3 |
PREMACURE AB
Organization address
address: DAG HAMMARSKJOLDS VAG 60 contact info |
SE (UPPSALA) | participant | 790˙160.99 |
| 4 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 679˙896.00 |
| 5 |
CHILDREN'S HOSPITAL CORPORATION
Organization address
address: LONGWOOD AVENUE 300 contact info |
US (BOSTON) | participant | 644˙745.00 |
| 6 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 528˙489.20 |
| 7 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 461˙448.00 |
| 8 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 461˙448.00 |
| 9 |
ISTITUTO GIANNINA GASLINI
Organization address
address: VIA GEROLAMO GASLINI 5 contact info |
IT (GENOVA) | participant | 421˙454.40 |
| 10 |
MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH
Organization address
address: ASPENHAUSTRASSE 25 contact info |
DE (REUTLINGEN) | participant | 323˙080.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. The PREVENTROP consortium proposes to conduct preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trial) of an EU designated orphan medicinal product. This orphan medicinal product has been granted the EU orphan designation. We have completed both a Phase I study and the first section of the Phase II study administering the growth factor complex IGF-I/IGFBP-3 (Premiplex®) successfully to preterm infants in order to prevent ROP– a discovery that we have taken from bench to bedside. Due to improved neonatal care, the survival of preterm babies has increased dramatically during the last decades. The downside of this improvement in survival rates is higher morbidity affecting these vulnerable infants. It should be emphasised that in a preterm infant any lasting morbidity will have a negative impact on the quality of life for a whole life span for both the individual and their families. One of the most severe morbidities affecting these infants is retinopathy causing severe visual impairment and blindness. Our research findings have rendered several editorials pointing at the hope of prevention strategies which if successful will change the paradigm for ROP and other morbidities in preterm infants. There are three major impacts of the present proposal; (1) clinical availability of a new orphan designated drug product, Premiplex®, and (2) improved care of preterm infants and (3) a significant contribution towards the goal of the International Rare Disease Research Consortium (IRDiRC) by delivering one new therapy for a rare disease.'
Introduzione (Teaser)
A large multi-disciplinary European consortium is underway to develop a novel drug for preventing blindness in prematurely born infants.